The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Design and evaluation of antibacterials crosslinked chitosan nanoparticle as a novel carrier for the delivery of metronidazole to treat bacterial vaginosis
Abstract
Bacterial vaginosis (BV) is a recurring, chronic infection that is difficult to treat due to the limited bioavailability of antimicrobials within vaginal epithelial cells. Vaginal administration, because of lower dosing and systemic exposure offers a viable option for treating vaginal infections. In this study, Metronidazole-loaded chitosan nanoparticles were synthesised employing borax (BX) or tannic acid (TA) as an antimicrobial crosslinking agent for treating BV. The prepared NPs were characterized for various physical, physicochemical, pharmaceutical, thermal and antibacterial properties. Morphological investigation revealed that nanoparticles prepared from 0.5 % w/v chitosan, 1.2 % w/v BX, and 0.4 % w/v metronidazole (MTZ) were non-spherical, with particle sizes of 377.4 ± 37.3 nm and a zeta potential of 34 ± 2.1 mV. The optimised formulation has MIC values of 24 ± 0.5 and 59 ± 0.5 μg/mL, against Escherichia coli (E.coli) and Candida albicans (C.albicans) respectively. The results of DSC and XRD demonstrated no change in the physical state of the drug in the finished formulation. Under simulated vaginal fluid, the optimised formulation demonstrates a cumulative drug release of about 90 % within 6h. The prepared borax crosslinked NPs exhibit anti-fungal activities by inhibiting ergosterol synthesis. The in-vivo antibacterial data indicated a comparable reduction in bacterial count compared to the marketed formulation in female Swiss albino mice treated with optimised nanoparticles. According to histopathological findings, the prepared nanoparticle was safe for vaginal use. Based on the experimental findings, it was concluded that MBCSNPs, due to their good physiochemical and antimicrobial properties, could serve as a potential topical alternative for treating BV and reducing fungal infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Particularly relevant for mucosal delivery, chitosan‐based nanoparticles, derived from the deacetylation of chitin, combine low toxicity, biocompatibility, and intrinsic antimicrobial properties with strong mucoadhesive capacity, thereby prolonging retention at the site of infection and facilitating localized drug release [31].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [31]
Citations
Cites
Fan, W., Yan, W., Xu, Z., & Ni, H. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.09.042 · Cited by 930
Development and characterisation of chitosan nanoparticles for siRNA delivery
Katas, H., & Alpar, H. O. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.021 · Cited by 643
Antibacterial Activity of Chitosan Nanoparticles: A Review
Chandrasekaran, M., Kim, K., & Chun, S. C. (2020) · Processes · doi:10.3390/pr8091173 · Cited by 470
Aydın, R. S. T., & Pulat, M. (2012) · Journal of Nanomaterials · doi:10.1155/2012/313961 · Cited by 326
Preparation and Characterization of Chitosan-Based Nanoparticles
Bodnár, M., Hartmann, J. F., & Borbely, J. D. (2005) · Biomacromolecules · doi:10.1021/bm0502258 · Cited by 314
Lee, S. J., Gwak, M. A., Chathuranga, K., Lee, J., Koo, J., & Park, W. H. (2022) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2022.108249 · Cited by 262
In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles
Nogueira-Librelotto, D. R., Tavano, L., Mitjans, M., Pérez, L., Infante, M. R., & Vinardell, M. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.005 · Cited by 205
Hejjaji, E. M. A., Smith, A. M., & Morris, G. A. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.185 · Cited by 154
Algharib, S. A., Dawood, A. S., Zhou, K., Chen, D., Li, C., Meng, K., Zhang, A., Luo, W., Ahmed, S., Huang, L., et al. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132129 · Cited by 153
Amin, M. K., & Boateng, J. S. (2022) · Marine Drugs · doi:10.3390/md20030156 · Cited by 152
Hyaluronic acid and chitosan-based nanosystems: a new dressing generation for wound care
Vigani, B., Rossi, S., Sandri, G., Bonferoni, M. C., Caramella, C. M., & Ferrari, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1634051 · Cited by 126
Matos, B. N., Pereira, M. N., Bravo, M. D. O., Filho, M. C., Saldanha‐Araújo, F., Gratieri, T., & Gelfuso, G. M. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.001 · Cited by 121
Antifungal mechanisms supporting boric acid therapy of Candida vaginitis
Seta, F. D., Schmidt, M., Vu, B., Essmann, M., & Larsen, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn486 · Cited by 119
Efficacy of ferulic acid encapsulated chitosan nanoparticles against Candida albicans biofilm
Panwar, R., Pemmaraju, S. C., Sharma, A. K., & Pruthi, V. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.02.007 · Cited by 106
Characterization and Treatment of Recurrent Bacterial Vaginosis
Faught, B. M., & Reyes, S. (2019) · Journal of Women s Health · doi:10.1089/jwh.2018.7383 · Cited by 104
Al‐Nemrawi, N. K., Alsharif, S. S. M., & Dave, R. H. (2018) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2018v10i5.26375 · Cited by 97
Jia, C., Cao, D., Ji, S., Zhang, X., & Muhoza, B. (2020) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2020.105717 · Cited by 96
Borax Mediated Layer-by-Layer Self-Assembly of Neutral Poly(vinyl alcohol) and Chitosan
Manna, U., & Patil, S. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9025333 · Cited by 90
MubarakAli, D., LewisOscar, F., Gopinath, V., Alharbi, N. S. H. A., Alharbi, S. A., & Thajuddin, N. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.11.043 · Cited by 83
Sreeharsha, N., Rajpoot, K., Tekade, M., Kalyane, D., Nair, A. B., Venugopala, K. N., & Tekade, R. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100920 · Cited by 77
Metronidazole for the treatment of vaginal infections
Sobel, R., & Sobel, J. D. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1035255 · Cited by 76
Controlled-release biodegradable nanoparticles: From preparation to vaginal applications
Martínez‐Pérez, B., Quintanar‐Guerrero, D., Tapia-Tapia, M., Tamayo, R. C., Zambrano‐Zaragoza, M. L., Alcalá-Alcalá, S., Mendoza‐Muñoz, N., & Piñón‐Segundo, E. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.11.029 · Cited by 76
Mucoadhesive and mucopenetrating chitosan nanoparticles for glycopeptide antibiotic administration
Abruzzo, A., Giordani, B., Miti, A., Vitali, B., Zuccheri, G., Cerchiara, T., Luppi, B., & Bigucci, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120874 · Cited by 76
Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development
Wong, T. W., Dhanawat, M., & Rathbone, M. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.924499 · Cited by 75
Pandey, P., Dua, K., & Dureja, H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.08.084 · Cited by 72
Yang, S., Liu, L., Chen, H., Wei, Y., Dai, L., Liu, J., Yuan, F., Mao, L., Li, Z., Chen, F., et al. (2020) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2020.106258 · Cited by 70
Rossi, S., Vigani, B., Sandri, G., Bonferoni, M. C., Caramella, C. M., & Ferrari, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1645117 · Cited by 68
Cheow, W. S., Chang, M. W., & Hadinoto, K. (2010) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2010.1116 · Cited by 67
Formulation and Evaluation of Gastroretentive Dosage Forms of Clarithromycin
Nama, M., Gonugunta, C. S. R., & Veerareddy, P. R. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-008-9038-8 · Cited by 65
Kumar, A., Cover, N. F., Lai-Yuen, S. K., & Parsons, A. K. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27328 · Cited by 65
Qiu, Y., Xu, D. Q., Sui, G., Wang, D., Wu, M., Han, L., Mu, H., & Duan, J. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.090 · Cited by 61
Hombach, M., Maurer, F. P., Pfiffner, T., Böttger, E. C., & Furrer, R. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02351-15 · Cited by 58
Comparison of SEM and VPSEM imaging techniques with respect toStreptococcus mutansbiofilm topography
Weber, K., Délben, J. A., Bromage, T. G., & Duarte, S. (2013) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12334 · Cited by 55
Cirri, M., Maestrelli, F., Scuota, S., Bazzucchi, V., & Mura, P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120375 · Cited by 55
Gustin, A. T., Thurman, A. R., Chandra, N., Schifanella, L., Alcaide, M. L., Fichorova, R. N., Doncel, G. F., Gale, M., & Klatt, N. R. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.09.018 · Cited by 54
Bensouiki, S., Belaib, F., Sindt, M., Rup-Jacques, S., Magri, P., Ikhlef, A., & Méniai, A.-H. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131298 · Cited by 48
Binesh, N., Farhadian, N., & Mohammadzadeh, A. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111691 · Cited by 38
Sabbagh, H. A. K., Hussein‐Al‐Ali, S. H., Hussein, M. Z., Abudayeh, Z. H. M., Ayoub, R., & Abudoleh, S. M. (2020) · Polymers · doi:10.3390/polym12040772 · Cited by 32
O'Brien, V. P., Gilbert, N., Lebratti, T. J., Agarwal, K., Foster, L. R., Shin, H.-N., & Lewis, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219941 · Cited by 23
Smith, R. A., Walker, R. C., Levit, S. L., & Tang, C. (2019) · Polymers · doi:10.3390/polym11050749 · Cited by 22
Poloxamer Modified Chitosan Nanoparticles for Vaginal Delivery of Acyclovir
Deshkar, S. S., Sikchi, S., Thakre, A., & Kale, R. (2021) · Pharmaceutical Nanotechnology · doi:10.2174/2211738508666210108121541 · Cited by 22
Application of multiple regression analysis in optimization of metronidazole-chitosan nanoparticles
Sabbagh, H. A. K., Abudayeh, Z. H. M., Abudoleh, S. M., Alkrad, J. A., Hussein, M. Z., & Hussein‐Al‐Ali, S. H. (2019) · Journal of Polymer Research · doi:10.1007/s10965-019-1854-x · Cited by 21
Current trends in chitosan based nanopharmaceuticals for topical vaginal therapies
Nayak, R., Kar, B., Ghosh, G., & Rath, G. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.045 · Cited by 19
Self-citationElgendy, A. M., Mohammed, M. A. A., Ghallab, M. M. I., AZIZ, M. O. A., & Ibrahim, S. (2021) · Iranian Journal of Parasitology · doi:10.18502/ijpa.v16i1.5509 · Cited by 13
Arias, J. L., Martínez-Soler, G. I., López-Viota, M., & Ruiz, M. (2010) · Letters in Drug Design & Discovery · doi:10.2174/157018010790225831 · Cited by 10
Investigation of Oligosaccharides for Prebitoic Action on Vaginal Lactobacilli
Mahore, J. G., Rohit, B., & Deshkar, S. S. (2017) · Journal of Young Pharmacists · doi:10.5530/jyp.2017.9.98 · Cited by 8
Nagaoka, S., Saita, K., Kobayashi, S., Horikawa, M., Shirosaki, T., Takafuji, M., & Ihara, H. (2010) · Chemistry Letters · doi:10.1246/cl.2010.935 · Cited by 3
Formulation and in vitro evaluation of polymeric metronidazole nanoparticles
Ovenseri, A. C., & Halilu, E. M. (2022) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2022.35.5.reg.1333-1338.1 · Cited by 3
Gupta, M., Dutta, R., Majumdar, S., & Sasmal, S. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3238421 · Cited by 1
Research works printed but not linked: 2
- Chávez de Paz, 2011, Antimicrobial effect of chitosan nanoparticles on, Streptococcus mutans biofilms, 77, 3892
- Dinesh, 2013, Study of antifungal activity of boric acid on vaginal pathogens, Int. J. Adv. Biotechnol., 4, 319
Cited by
Sorted by citations
Chitosan and Its Nanoparticles: A Multifaceted Approach to Antibacterial Applications
Akdaşçi, E., Duman, H., Eker, F., Bechelany, M., & Karav, S. (2025) · Nanomaterials · doi:10.3390/nano15020126 · Cited by 99
Tamil Mani Subi, M., Selvasudha, N., & Vasanthi, H. R. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104012 · Cited by 33
Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases
Sinani, G., Sessevmez, M., & Şenel, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091201 · Cited by 31
Harini, A., & Ilaiyaraja, P. (2025) · RSC Advances · doi:10.1039/d5ra01788b · Cited by 24
Satpathy, B., Rajwar, T. K., Mishra, A. K., Saha, I., Rai, V. K., Sahoo, R. K., Halder, J., Mahanty, R., Manoharadas, S., Al‐Tamimi, J., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05137-4 · Cited by 19
Self-citation
Metadata
- Authors
- Nayak, R., Halder, J., Rajwar, T. K., Pradhan, D., Dash, P., Das, C., Rai, V. K., Kar, B., Ghosh, G., & Rath, G.
- Affiliations
- Siksha O Anusandhan University (IN)
- Corresponding author
- Rath, Goutam
- ORCID
- Venue
- Microbial Pathogenesis
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 186
- Pages
- 106494
- ISSN
- 0882-4010 (ISSN-L)
- OpenAlex
- W4389410287
- Cited by
- 15
- References
- 49
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Microbial Pathogenesis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Biotechnology, Ministry of Science and Technology, India (BT/INF/22/SP45078/2022)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Keywords
- bacterial vaginosis, chitosan nanoparticles, metronidazole, borax crosslinking, tannic acid crosslinking, vaginal drug delivery, antibacterial nanoparticles, antifungal activity, Candida albicans, Escherichia coli, nanoparticle safety
- MeSH terms
- Animals, Anti-Bacterial Agents, Borates, Drug Carriers, Female, Humans, Metronidazole, Particle Size, Vaginosis, Bacterial, Chitosan, Mice, Nanoparticles, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review